Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo

8 Oct 2016

Abstract excerpt

The clinical potential of PARP-1 inhibitors has been recognized >10years ago, prompting intensive research on their pharmacological application in several branches of medicine, particularly in oncology. However, natural or acquired resistance of tumors to known PARP-1 inhibitors poses a serious problem for their clinical implementation. Present study aims to reignite clinical interest to PARP-1 inhibitors by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Integrated Circuits and Semiconductor Failure Analysis
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27727003
DOI: 10.1016/j.ebiom.2016.10.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivoPMID 27727003Read ↗

Structural Implications for Selective Targeting of PARPsSemantic proximity Read ↗

Therapeutic Targeting of Poly(ADP‐Ribose) Polymerase‐1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future OpportunitiesSemantic proximity Read ↗

An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer TherapySemantic proximity Read ↗

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?Semantic proximity Read ↗

PARP inhibitorsSemantic proximity Read ↗

PARP inhibitors in cancer therapy: an updateSemantic proximity Read ↗

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host InteractionsSemantic proximity Read ↗

How to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ationSemantic proximity Read ↗

Mechanism of Action of PARP InhibitorsSemantic proximity Read ↗

Recent Progress in Poly(ADP–Ribose) Polymerase‐1 Inhibitors for Application in CancerSemantic proximity Read ↗

Poly (ADP-ribose) polymerase inhibitors in cancer therapySemantic proximity Read ↗

Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.